Sustainable sales is the key for sure. l think Phase 2 results, FDA approval and collaborations with big pharma are going to move the current SP substantially regardless of lagging sales anyway. Sales are just assumed to follow when analitical labs return to core business. Just my impression though. The predective accuracy of the test, cost advantage and easy roll out, mean its almost a given, that Promarker D is going to revolutionarize Diabetic Kidney Disease treatment. Especially with no competitors imminent.
Sustainable sales is the key for sure. l think Phase 2 results,...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.005(1.37%) |
Mkt cap ! $60.56M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 35.0¢ | $51.50K | 144.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 18336 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 9405 | 1 |
View Market Depth
| Last trade - 15.58pm 30/07/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |